¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"time study"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
family study
°¡Á·Á¶»ç
longitudinal study
ÃßÀû¿¬±¸
molecular genetic study
ºÐÀÚÀ¯ÀüÇа˻ç
neurophysiological study
½Å°æ»ý¸®ÇÐÀû°Ë»ç
observational study
°üÂû¿¬±¸
pilot study
¿¹ºñ¿¬±¸
population study
Àα¸Á¶»ç
preclinical study
ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
pressure flow study
¾Ð·Â¿ä·ù°Ë»ç
prospective cohort study
ÀüÇâÄÚȣƮ¿¬±¸
prospective study
ÀüÇ⿬±¸, °èȹ¿¬±¸
retrospective cohort study
ÈÄÇâÄÚȣƮ¿¬±¸
retrospective study
ÈÄÇ⿬±¸
study
1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
study design
¿¬±¸¼³°è
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
single blinding study
´Ü¼ø¸Í°Ë¹ý
urodynamic study
¿ä¿ªµ¿Çа˻ç
time
½Ã°£
acquisition time
ȹµæ½Ã°£
activated partial thromboplastin time
Ȱ¼ºÈºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
bleeding time
ÃâÇ÷½Ã°£
clot retraction time
ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´ÅðÃà½Ã°£
coagulation time
ÀÀ°í½Ã°£
colonic transit time
´ëÀåÅë°ú½Ã°£
diastolic filling time
È®Àå±âÃæ¸¸½Ã°£
diffusion time
È®»ê½Ã°£
expiratory pause time
³¯¼ûÈĽ¬´Â½Ã°£, È£±âÈÄÈÞÁö½Ã°£
expiratory phase time
³¯¼û½Ã°£, È£±â½Ã°£
exposure time
³ëÃâ½Ã°£, Æø·Î½Ã°£
gastric emptying time
À§¹èÃâ½Ã°£
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
family study
°¡Á·Á¶»ç
feasibility study
°¡´É¼º¿¬±¸
first pass study
ÀÏÂ÷Åë°ú°Ë»ç
follow-up study
ÃßÀûÁ¶»ç
infection control study
°¨¿°°ü¸®Á¶»ç
intervening study
°³ÀÔ¿¬±¸
longitudinal study
ÃßÀû¿¬±¸
microbiologic study
¹Ì»ý¹°Çа˻ç
migrant study
ÀÌÁֹבּ¸
mixing study
È¥ÇÕ°Ë»ç
molecular genetic study
ºÐÀÚÀ¯ÀüÇа˻ç
neurophysiological study
½Å°æ»ý¸®ÇÐÀû°Ë»ç
nonconcurrent study
ºñµ¿½ÃÀû¿¬±¸
observational study
°üÂû¿¬±¸
pilot study
¿¹ºñ½ÇÇè
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
MTT=£¾mean tidal time
Æò±Õ¼øÈ¯½Ã°£.
Russells viper venom time
·¯¼¿¹ÙÀÌÆÛº£³ð½Ã°£
T.G.C (time gain compensation)
½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ), °Å¸®(±íÀÌ) °ÔÀÎ º¸»ó
T.G.C (time gain compensation)
½Ã°£ °ÔÀÎ º¸»ó
T1 relaxation time
T1 ÀÌ¿Ï ½Ã°£
T2 (spin spin) relaxation time
T2(½ºÇɽºÇÉ) À̿Ͻð£
T2 relaxation time
T2 ÀÌ¿Ï ½Ã°£
TM scan(Time motion)
½Ã°£ ¿îµ¿ ¹æ½Ä
TM-scan(Time motion)
½Ã°£ ¿îµ¿ ¹æ½Ä (ãÁÊà ê¡ÔÑ Û°ãÒ)
TOF (time of flight)
È帧 ½Ã°£ TOF(Ƽ¿À¿¡ÇÁ), À¯Ã¼ ¼Óµµ °?
acquisition time
ȹµæ ½Ã°£
activated clotting time
Ȱ¼ºÈÀÀ°í½Ã°£
activated coagulation time(ACT)
Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
activated coagulation time=ACT
Ȱ¼ºÈ ÀÀ°í½Ã°£
activated partial prothrombin time
Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
molecular genetic study
ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
nested case control study
phase 1 study
ÀÓ»óÁ¦1»ó½ÃÇè.
pilot study
¿¹ºñ½ÇÇè.
population study
Àα¸Á¶»ç
preclinical study
ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
pressure flow study
¾Ð·ù·® Á¶»ç
pressure-perfusion study
¾Ð·Â°ü·ù°Ë»ç
prospective study
°èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
retrospective study
ÈÄÇâÀû¿¬±¸
single blind study
´ÜÀÏ<¼ø>¸Í°Ë¹ý.
tracer study
ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
twin study
½Ö»ý¾Æ¿¬±¸(¡æÚϼ).
twin study
½Ö»ý¾Æ¿¬?¡æÚϼ)
urodynamic study
¿ä¿ªµ¿ÇÐ °Ë»ç
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½